SWOG clinical trial number
S1826

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Closed
Phase
Accrual
100%
Abbreviated Title
Phase III Study of AVD plus nivolumab or BV in pts >/= 12 years in newly diagnosed, advanced cHL
Status Notes
Temporary Closure: Effective Wednesday, October 05, 2022, 12:00 p.m. Pacific Time
Activated
07/19/2019
Closed
12/01/2022
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE

Research committees

Lymphoma

Treatment

Doxorubicin Filgrastim Vinblastine Sulfate Radiation Therapy Pegfilgrastim Nivolumab Brentuximab Vedotin Dacarbazine RT

Eligibility Criteria Expand/Collapse

See Section 5.0 of the S1826 protocol posted on www.ctsu.org

Publication Information Expand/Collapse

2024

Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children

A Lo;A Liu;Q Liu;Y Yasui;S Catellino;K Kelly;A Hererra;JW Friedberg;D Friedman;C Schwartz;Q Pei;S Kessel;S Bergeron-Gravel;H Dama;K Roberts;L Constine;D Hodgson JAMA Network Open Jan 2;7(1):e2351062

PMid: PMID38241048 | PMC number: PMC10799264

Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children

A Lo;A Liu;Q Liu;Y Yasui;S Castellino;K Kelly;A Herrera;JW Friedberg;D Friedman;C Schwartz;Q Pi;S Kessel;S Bergeron-Gravel;H Dama;K Roberts;L Constine;D Hodgson JAMA Network Open Jan 2;7(1):e2351062. doi: 10.1001/jamanetworkopen.2023.51062

2023

Nivolumab-AVD Improves Progression-Free Survival (PFS) Compared to Brentuximab Vedotin-AVD in Advanced Stage (AS) Classic Hodgkin Lymphoma (HL), Results of SWOG S1826

A Herrera;H Li;S Costellino;S Rutherford;A Evens;K Davidson;A Punnett;D Hodgson;S Parsons;S Ahmed;C Casulo;N Bartlett;J Song;R Little;M LeBlanc;B Kahl;J Leonard;K Kelly;S Smith;J Friedberg J Clin Oncol 41, 2023 (suppl 17; abstr LBA4); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), oral plenary session

Nivolumab-AVD Improves Progression-Free Survival (PFS) Compared to Brentuximab Vedotin-AVD in Advanced Stage (AS) Classic Hodgkin Lymphoma (HL), Results of SWOG S1826

A Herrera;M LeBlanc;S Castellino;H Li;S Rutherford;A Evens;K Davison;A Punnett;D Hodgson;S Parsons;S Ahmed;C Casulo;N Bartlett;J Tuscano;M Mei;B Hess;R Jacobs;H Saeed;P Torka;B Hu;C Moskowitz;S Kaur;G Goyal;C Forlenza;A Doan;A Lamble;P Kumar;S Chowdury;B Brinker;N Sharma;A Singh;K Blum;W Macon;A Perry;A Kovach;L Constine;L Kostakoglu Shields;A Prica;R Little;M Shipp;M Crump;B Kahl;J Leonard;S Smith;J Song;K Kelly;JW Friedberg Hematology Oncology Vol 41 Issue S2 Supplement; ICML (June 13 to June 17, 2023, Lugano, Switzerland), oral, plenary session

Progression-Free Survival (PFS) and toxicity with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL), Results of SWOG S1826

S Castellino;H Li;A Herrera;A Punnett;M LeBlanc;F Keller;R Drachtman;A Lamble;C Forlenza;A Doan;S Rutherford;A Evens;D Hodgson;S Parsons;R Little;M Smith;J Song;S Smith;JW Friedberg;K Kelly ASH Annual Meeting (Dec 9-12, 2023, San Diego), oral

Nivolumab-AVD is better tolerated and improves progression-free survival compared to Bv-AVD in older patients (aged =60 years) enrolled on SWOG S1826

S Rutherford;H Li;A Herrera;M LeBlanc;S Ahmed;K Davison;C Casulo;N Bartlett;J Tuscano;B Hess;P Torka;P Kumar;R Jacobs;J Song;S Castellino;B Kahl;J Leonard;S Smith;JW Friedberg;A Evens ASH Annual Meeting (Dec9-12,2023, San Diego, CA), oral

2021

An Intergroup Approach for Advanced Stage Classical Hodgkin Lymphoma (cHL) in Adolescents and Young Adults (AYA): SWOG S1826

S Castellino;M Leblanc;A Herrera;S Parsons;A Punnett;D Hodgson;S Rutherford;N Kahn;L Constine;K Davidson;A Prica;JW Friedberg;K Kelly INTERNATIONAL SYMPOSIUM ON CHILDHOOD, ADOLESCENT AND YOUNG ADULT HODGKIN LYMPHOMA (ISCAYAHL) (5/13-16/20, Berlin, Germany)

The Evolution of Children’s Oncology Group Hodgkin Lymphoma Trials: Predicted Impact on Late Cardiac Toxicity

A Lo;A Liu;Y Yasui;S Castellino;K Kelly;A Herrera;JW Friedberg;D Friedman;C Schwartz;K Roberts;L Constine;D Hodgson American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), oral, #881

Addressing the Paucity of AYA Clinical Trials Through Pediatric and Adult Partnership

S Parsons;M Roth AYA Global Congress (December 2, 2021), plenary presentation, oral, no publication

2020

An Intergroup Collaboration for Advanced Stage Classical Hodgkin Lymphoma (cHL) in Adolescents and Young Adults (AYA): SWOG S1826

S Castellino;M LeBlanc;A Herrera;S Parsons;S Punnett;D Hodgson;S Rutherford;N Kahn;L Constine;K Davidson;A Prica;JW Friedberg;K Kelly J Clin Oncol 38: 2020 (suppl; abstr TPS8067); American Society of Clinical Oncology 2020 Annual Meeting, TIPS poster

Reply to LTE, Interim PET assessment of advanced Hodgkin Lymphoma: is it sufficient? [Letter to Editor]

D Stephens;H Schoder;H Li;J Friedberg Journal of Nuclear Medicine Sep 11;jnumed.120.242685. doi: 10.2967/jnumed.120.242685. Online ahead of print.

PMid: PMID32917781

SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

A Herrera;H Li;S Castellino;S Rutherford;A Evens;K Davidson;A Punnett;L Constine;D Hodgson;S Parsons;A Prica;L Kostakoglu;M Shipp;M Leblanc;C Laubach;M Crump;B Kahl;JP Leonard;K Kelly;S Smith;JW Friedberg American Society of Hematology (December 5-8, 2020, virtual), poster presentation

Evaluation of Activation of a National Cancer Trials Network (NCTN) trial for Hodgkin Lymphoma (HL) at Children’s Oncology Group (COG) Institutions

S Castellino;A Punnett;S Parsons;N Degroote;S Muehle;M Roth;A Herrera;JW Friedberg;N Siebel;K Kelly American Society of Hematology (December 5-8, 2020, virtual), poster presentation